Effect of Anticoagulant Use on Coagulation Parameters in Covid-19 Comorbid Diabetic Patients

Nurma Febria; Fatma Sri Wahyuni; Yufrialdi Yufrialdi

doi:10.36929/jpk.v13i2.853

Nurma Febria Universitas Andalas, Padang, Indonesia
Fatma Sri Wahyuni Universitas Andalas, Padang, Indonesia
Yufrialdi Yufrialdi Universitas Andalas, Padang, Indonesia

DOI: https://doi.org/10.36929/jpk.v13i2.853

Keywords: Anticoagulant, Covid 19, Diabetes

Abstract

Coagulation disorders, one of the causes of death of severe Covid-19 patients and comorbidities that also affect coagulation is Diabetes Mellitus. In the guidelines, it is recommended to use prophylactic anticoagulants, namely Unfractionated Heparin (UFH) and Low Molecular Weight Heparin (LMWH) to overcome the problem of this coagulation disorder by paying attention to the value of coagulation parameters, namely, D-Dimer, PT, APTT and platelet values. The purpose of this study was to see the relationship between the use of prophylactic anticoagulants with a decrease / increase in the value of the coagulation parameter. The research design was retrospective pre-post test cohort study with research subjects of comorbid Covid-19 Diabetes patients treated in the ICU of RSUP Dr.M Djamil Padang. As a result, in the group of patients using UFH there was a significant decrease in D-Dimer values (p = 0.001) while the LMWH group was not significantly related (p = 0.05). For the association of anticoagulants with PT values, APTT in both groups was not significant. As for platelet values, there was a significant decrease in the UFH group. Conclusion for severe Covid-19 patients with comorbid Diabetes The use of UFH is recommended as a therapeutic option.

References

[1] W. Y et al., “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China,” Lancet, 2020.
[2] A. Cuker et al., “American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19,” Blood Adv., 2021, doi: 10.1182/bloodadvances.2020003763.
[3] R. Zheng et al., “COVID-19-associated coagulopathy: thromboembolism prophylaxis and poor prognosis in ICU,” Exp. Hematol. Oncol., 2021, doi: 10.1186/s40164-021-00202-9.
[4] E. Burhan et al., Cedera miokardium pada infeksi COVID-19. 2022.
[5] Arikunto S., “Prosedur penelitian suatu pendekatan praktik.,” Jakarta: Rineka Cipta. 2006.
[6] B. S. Joly, V. Siguret, and A. Veyradier, “Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19,” Intensive Care Medicine. 2020. doi: 10.1007/s00134-020-06088-1.
[7] Zahtamal and dkk, “Faktor-Faktor Risiko Pasien Diabetes Melitus,” Ber. Kedokt. Masy., 2007.
[8] G. Hale and M. Brenner, “Risks and Benefits of Low Molecular-Weight Heparin and Target-Specific Oral Anticoagulant Use for Thromboprophylaxis in Medically Ill Patients,” American Journal of Cardiovascular Drugs. 2015. doi: 10.1007/s40256-015-0122-7.
(9) Terpos, E. et al. (2020) ‘Hematological findings and complications of COVID-19’, American Journal of Hematology [Preprint]. doi:10.1002/ajh.25829.
(10) Y, W. et al. (2020) ‘Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China’, The Lancet [Preprint].